These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 6279291)

  • 1. Diphtheria toxin treatment of human advanced cancer.
    Buzzi S
    Cancer Res; 1982 May; 42(5):2054-8. PubMed ID: 6279291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
    Moulton HM; Yoshihara PH; Mason DH; Iversen PL; Triozzi PL
    Clin Cancer Res; 2002 Jul; 8(7):2044-51. PubMed ID: 12114402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
    Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
    Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
    Ramanathan RK; Lee KM; McKolanis J; Hitbold E; Schraut W; Moser AJ; Warnick E; Whiteside T; Osborne J; Kim H; Day R; Troetschel M; Finn OJ
    Cancer Immunol Immunother; 2005 Mar; 54(3):254-64. PubMed ID: 15372205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of human antibody responses to diphtheria toxin subunits A and B in various age groups.
    Karakus R; Caglar K; Aybay C
    Clin Microbiol Infect; 2007 Nov; 13(11):1065-71. PubMed ID: 17711484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
    Potala S; Sahoo SK; Verma RS
    Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
    Liu ZF; Guo QS; Zhang XQ; Yang XG; Guan F; Fu Z; Wang MY
    Am J Clin Oncol; 2008 Jun; 31(3):259-63. PubMed ID: 18525305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of treatment of metastatic melanoma and solid tumours adopting a derivative of diphtheria toxin: cross-reacting material 197.
    Fiorentini G; Banfi R; Dentico P; Moriconi S; Turrisi G; Pelagotti F; Rossi S; Montagnani F
    In Vivo; 2013; 27(2):197-202. PubMed ID: 23422478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
    Nemunaitis J; Cunningham C; Senzer N; Gray M; Oldham F; Pippen J; Mennel R; Eisenfeld A
    Cancer Invest; 2005; 23(8):671-6. PubMed ID: 16377585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines.
    Nordøy T; Husebekk A; Aaberge IS; Jenum PA; Samdal HH; Flugsrud LB; Kristoffersen AC; Holte H; Kvaløy S; Kolstad A
    Bone Marrow Transplant; 2001 Oct; 28(7):681-7. PubMed ID: 11704791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.